Tiny RNA switches to turn AAV gene therapies on, off, or down
Synthetic RNA Switch-Based Temporal and Dose Control of in Vivo Gene Therapies
This work develops small RNA switches that would let doctors adjust or stop one-time AAV gene therapies for people who receive them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of Massachusetts Med Sch Worcester NIH-funded |
| Lab location | 1 site (Worcester, United States) |
| Project ID | NIH-11292427 on NIH RePORTER |
What this research studies
If I were a patient getting a one-time AAV gene therapy, this project aims to add a tiny RNA switch to the therapeutic gene so its output can be changed later by giving a short, safe oligonucleotide drug. The team designs the switch to fit inside the limited space of AAV vectors and tests it in cells and animals to show it can be turned up, down, or off without toxic drugs. Because the control molecule is a morpholino oligo class already used safely in people, the approach is intended to be compatible with future human use. The work focuses on making long-lasting gene treatments more adjustable and safer if a condition changes or side effects appear.
Who could benefit from this research
Good fit: People who are receiving or being considered for single-dose AAV-based gene therapies and who want the option to control or stop the therapy later would be the most relevant candidates.
Not a fit: Patients whose treatments do not use AAV delivery, who are not candidates for gene therapy, or who need an immediate short-term intervention would likely not benefit from this work.
Why it matters
Potential benefit: If successful, patients could get one-time gene therapies that doctors can later adjust or shut off to reduce long-term risks and respond to changing health needs.
How similar studies have performed: Some previous AAV-compatible switches worked in animals but depended on drugs with safety problems, while this RNA-plus-morpholino approach is newer with promising preclinical results but not yet proven in humans.
Where this research is happening
Worcester, United States
- Univ of Massachusetts Med Sch Worcester — Worcester, United States (Active)
Researchers
- Principal investigator: Zhong, Guocai — Univ of Massachusetts Med Sch Worcester
- Study coordinator: Zhong, Guocai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.